Symbols

GMAB

Genmab·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 6

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

High Cash/net Profit Ratio

Revenue Beats Expectation

EPS Beats Expectation

Bearish Abandoned Baby

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About GMAB

Genmab A/S

An international biotechnology company focused on creating and developing innovative antibody therapeutics

Industry

Pharmaceutical

Established Date

06/11/1998

Listing Date

07/18/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

2,682

Fiscal Year Ends

12-31

Website

www.genmab.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

Carl Jacobsens Vej 30, 2500 Valby, Denmark

Business

Introduction

Genmab A/S was incorporated on June 11, 1998. They are an international biotechnology company specializing in the treatment of antibodies for cancer and other diseases. Their core purpose is to improve the lives of patients by creating and developing innovative antibody products. The company's vision is to transform cancer treatments and advance its well-differentiated and well-tolerated antibody pipeline by launching its own patented product in 2025. They are building and expanding their late-stage development and commercial capabilities so that they can bring their proprietary products to market in the future.

Earnings Call

Q2/2025

Estimate EPS0.34

Actual EPS0.54

Estimate Revenue900.07M

Actual Revenue925.00M

Genmab's Q2 2025: Unraveling Contradictions in Rina-S, EPKINLY Launch, and HexaBody-OX40 Development Strategies

Aug 10,2025 11:37·
Earnings Decrypt

Company Financials

EPS

GMAB has released its 2025 Q3 earnings. EPS was reported at 0.65, versus the expected 0.45, beating expectations. The chart below visualizes how GMAB has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

GMAB has released its 2025 Q3 earnings report, with revenue of 1.02B, reflecting a YoY change of 25.25%, and net profit of 401.00M, showing a YoY change of 115.59%. The Sankey diagram below clearly presents GMAB's revenue sources and cost distribution.